Sodium–Glucose Cotransporter 2 Inhibitors and Kidney Outcomes: True Renoprotection, Loss of Muscle Mass or Both?

Inhibitors of sodium–glucose cotransporter 2 (SGLT2) have emerged as practice-changing treatments for patients with type 2 diabetes, reducing both the risk of cardiovascular events and kidney events. However, regarding the latter, caution is warranted, as these kidney endpoints are defined using glo...

Descripción completa

Detalles Bibliográficos
Autores principales: Post, Adrian, Groothof, Dion, Eisenga, Michele F., Bakker, Stephan J. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291210/
https://www.ncbi.nlm.nih.gov/pubmed/32466262
http://dx.doi.org/10.3390/jcm9051603

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291210/
https://www.ncbi.nlm.nih.gov/pubmed/32466262
http://dx.doi.org/10.3390/jcm9051603

Ejemplares similares